Only a narrow set of stem cell products are FDA approved, and none of them treat joint pain or aging. The U.S. Food and Drug Administration has cleared blood-forming transplants and a few named cell therapies for serious blood and immune diseases. Everything sold for knees, backs, hair, or “anti-aging” falls outside that approved list.
This guide lays out the approved products by name, explains what is not approved, and shows how to check any clinic’s claim. It pairs with our hub on whether stem cell therapy is legal in the US.
What “FDA approved” actually means
FDA approval means a product passed clinical trials and carries a specific approved use. The FDA reviews safety and effect data, then approves the product for a named condition. Approval is tied to that use, not to stem cells in general.
This matters because clinics blur the line. A product approved for one blood disease is not approved for a knee. Approval never transfers across uses on its own.
The FDA-approved stem cell products
The FDA has approved two broad groups: blood-forming transplants and a short list of named cell products. Here is the 2026 picture.
| Product or use | What it treats | Status |
|---|---|---|
| Hematopoietic stem cell transplant (bone marrow, peripheral blood) | Leukemia, lymphoma, other blood and immune disorders | Established approved use |
| Cord-blood products (e.g. approved HPC, cord blood units) | Blood-system reconstruction after transplant | FDA approved |
| Ryoncil (remestemcel-L) | Steroid-refractory acute GVHD in children | FDA approved, 2024 |
| Tregzi (allogeneic Treg immunotherapy with HSPC) | Used with matched-donor transplant for blood cancers | FDA approved, 2026 |
Ryoncil is the first approved mesenchymal stromal cell therapy, which matters because “mesenchymal stem cells” is the exact phrase orthopedic clinics use. Its approval is only for a pediatric transplant complication. Tregzi was approved in June 2026 for use alongside donor transplants.
What the FDA has NOT approved
The FDA has not approved any stem cell product for orthopedic pain, aging, or most chronic conditions. This is the list that surprises patients, so read it carefully.
- Knees, hips, shoulders, and other joints. No approved stem cell product exists for arthritis or joint injury.
- Back and spine pain. Not approved.
- Anti-aging, “wellness,” and IV longevity infusions. Not approved.
- Autism, MS, Parkinson’s, COPD, and similar claims. Not approved, and the FDA has warned specifically about these marketing claims.
- Hair loss and cosmetic “stem cell facials.” Not approved; many use PRP or exosomes, not stem cells.
If a clinic offers any of the above and calls it FDA approved, the claim is wrong.
FDA approved vs registered vs “in a trial”
Three phrases get used to sound official, and only one is approval. Knowing the difference protects you from a common sales tactic.
FDA approved means the product cleared review for a named use. This is the real thing.
FDA registered or FDA listed only means a facility filed paperwork saying it handles tissue. The FDA states plainly that registration is not endorsement or approval. Any tissue clinic can register.
“Part of an FDA trial” may be legitimate if there is a real Investigational New Drug filing. But a genuine trial does not charge large fees for unproven treatment and registers on ClinicalTrials.gov. Ask for the trial’s registration number and check it.
The mesenchymal stem cell trap
The phrase “mesenchymal stem cells” is approved for one narrow product, not for the injections most clinics sell. Ryoncil is a mesenchymal stromal cell therapy, and clinics lean on that fact. They imply their fat-derived or cord-derived joint injection shares Ryoncil’s approval. It does not.
Approval is product-specific and use-specific. A shared cell family means nothing legally. When a clinic points to Ryoncil to justify a knee injection, that is a signal to slow down, not to trust.
What about my own cells, same day?
A same-day procedure using your own minimally processed cells sits in a gray zone, not a clear approval. Some clinics draw your bone marrow or fat, spin it, and re-inject it in one visit. They argue this fits the tissue exemption because the cells are barely handled and go back into your body.
The FDA may treat some of these procedures as exempt, but many still fail the homologous-use test. Injecting fat-derived cells into a joint to change cartilage is often not the cells’ original job. So “your own cells” does not equal “FDA approved,” and it does not remove the risk. It only changes which rule the clinic is leaning on.
Ask the clinic to state plainly whether the product is FDA approved, exempt under the tissue rule, or unapproved. The answer for orthopedic and anti-aging use is almost never “approved.”
How to verify an approval yourself
You can confirm any approval in a few minutes using the FDA’s own lists. Do this before you pay anything.
- Open the FDA’s approved cellular and gene therapy products page.
- Look for the exact product name and its approved use.
- If the clinic names a “trial,” find its number on ClinicalTrials.gov.
- If nothing matches the product and your condition, it is not FDA approved.
A clinic that cannot point you to a real listing is telling you the answer by its silence. Our how to vet a clinic guide expands this into a full checklist, and our insurance coverage guide explains why unapproved status also means you pay out of pocket.
The bottom line on FDA approval
Stem cell therapy is FDA approved only for blood and immune uses and a few named products like Ryoncil and Tregzi. It is not approved for knees, backs, hair, or anti-aging in 2026. Learn the difference between approved, registered, and “in a trial,” and verify every claim on the FDA’s own site. When the approved list and your condition do not match, the reading is simple: the product is unapproved, and you are the one taking the risk.
Frequently asked questions
Is any stem cell therapy FDA approved in 2026?
Yes. The FDA has approved blood-forming stem cell transplants and a small set of named cell products, such as Ryoncil and several cord-blood products. None are approved for knee arthritis, back pain, or anti-aging.
Is stem cell therapy for knees FDA approved?
No. As of 2026 the FDA has not approved any stem cell product for knee arthritis or other orthopedic pain. Clinics offering knee injections sell them under a tissue exemption or as unapproved products.
What does 'FDA registered' mean on a clinic's website?
FDA registered is not FDA approved. Registration only means a facility told the FDA it handles human tissue. It does not mean the product was reviewed, tested, or cleared for any use. Treat the two phrases as completely different.
Is Ryoncil an FDA-approved stem cell therapy?
Yes. Ryoncil (remestemcel-L) is an FDA-approved mesenchymal stromal cell product. It is approved for steroid-refractory acute graft-versus-host disease in children, not for joints or general wellness.
Are cord blood or 'umbilical stem cell' injections FDA approved?
Only for specific blood-reconstitution uses. The FDA has approved certain cord-blood products to rebuild the blood system after transplant. Cord or umbilical products injected into joints or given by IV for other conditions are not approved.
How can I verify an FDA approval myself?
Search the FDA's approved cellular and gene therapy products list and the drug approval database. If a specific product and use are not listed there, it is not FDA approved, no matter what the clinic's brochure says.
Medical disclaimer. Medical Frontier is an independent educational resource. This page is for general information only and is not medical advice, diagnosis, or treatment, and does not create a doctor–patient relationship. Most regenerative therapies discussed here are not FDA-approved for the uses described and may be offered under limited exemptions or in clinical trials only. Always consult a licensed physician before making any treatment decision.